|
SERES THERAPEUTICS, Inc. (MCRB) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Seres Therapeutics, Inc. (MCRB) Bundle
¡Valoración de Simplify Seres Therapeutics, Inc. (MCRB) con esta calculadora DCF personalizable! Con Real Sieres Therapeutics, Inc. (MCRB) financieras y entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Sieres Therapeutics, Inc. (MCRB) en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.5 | 33.2 | 144.9 | 7.1 | 126.3 | 158.3 | 198.3 | 248.5 | 311.3 | 390.1 |
| Revenue Growth, % | 0 | -3.74 | 336.33 | -95.08 | 1672.24 | 25.29 | 25.29 | 25.29 | 25.29 | 25.29 |
| EBITDA | -59.9 | -77.3 | -56.7 | -237.5 | -85.4 | -128.8 | -161.3 | -202.1 | -253.3 | -317.3 |
| EBITDA, % | -173.73 | -232.76 | -39.14 | -3332.04 | -67.63 | -81.35 | -81.35 | -81.35 | -81.35 | -81.35 |
| Depreciation | 9.8 | 8.9 | 9.2 | 11.9 | 6.2 | 52.7 | 66.1 | 82.8 | 103.7 | 130.0 |
| Depreciation, % | 28.49 | 26.77 | 6.36 | 166.29 | 4.94 | 33.31 | 33.31 | 33.31 | 33.31 | 33.31 |
| EBIT | -69.8 | -86.2 | -65.9 | -249.4 | -91.7 | -132.3 | -165.8 | -207.8 | -260.3 | -326.2 |
| EBIT, % | -202.22 | -259.53 | -45.5 | -3498.33 | -72.57 | -83.61 | -83.61 | -83.61 | -83.61 | -83.61 |
| Total Cash | 94.8 | 253.6 | 290.7 | 181.3 | 128.0 | 158.3 | 198.3 | 248.5 | 311.3 | 390.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.8 | 9.4 | .0 | .0 | 8.7 | 12.8 | 16.0 | 20.0 | 25.1 | 31.4 |
| Account Receivables, % | 5.17 | 28.26 | 0 | 0 | 6.87 | 8.06 | 8.06 | 8.06 | 8.06 | 8.06 |
| Inventories | -29.7 | .0 | .0 | .0 | 29.6 | -19.8 | -24.8 | -31.1 | -39.0 | -48.8 |
| Inventories, % | -86.05 | 0.000003010688 | 0 | 0 | 23.47 | -12.52 | -12.52 | -12.52 | -12.52 | -12.52 |
| Accounts Payable | 4.9 | 4.0 | 13.7 | 17.4 | 3.6 | 43.9 | 54.9 | 68.8 | 86.3 | 108.1 |
| Accounts Payable, % | 14.08 | 12.1 | 9.48 | 244.67 | 2.88 | 27.71 | 27.71 | 27.71 | 27.71 | 27.71 |
| Capital Expenditure | -1.0 | -.6 | -9.6 | -9.8 | -8.0 | -37.2 | -46.6 | -58.4 | -73.2 | -91.7 |
| Capital Expenditure, % | -2.9 | -1.78 | -6.6 | -137.78 | -6.31 | -23.52 | -23.52 | -23.52 | -23.52 | -23.52 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -63.8 | -83.6 | -61.8 | -253.0 | -91.7 | -127.6 | -159.9 | -200.4 | -251.0 | -314.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -22.2 | -113.4 | -43.1 | -247.3 | -145.5 | -26.5 | -127.6 | -159.9 | -200.3 | -251.0 |
| WACC, % | 8.58 | 8.8 | 8.67 | 8.92 | 8.92 | 8.78 | 8.78 | 8.78 | 8.78 | 8.78 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -564.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -256 | |||||||||
| Terminal Value | -3,778 | |||||||||
| Present Terminal Value | -2,481 | |||||||||
| Enterprise Value | -3,045 | |||||||||
| Net Debt | 86 | |||||||||
| Equity Value | -3,131 | |||||||||
| Diluted Shares Outstanding, MM | 128 | |||||||||
| Equity Value Per Share | -24.46 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
- Real-World Data: Seres Therapeutics, Inc. (MCRB) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model tailored to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life MCRB Financials: Pre-filled historical and projected data for Seres Therapeutics, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Seres Therapeutics' intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Seres Therapeutics' valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Template: Download and open the Excel file containing Seres Therapeutics, Inc.'s (MCRB) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures to fit your analysis.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand the impact on valuation outcomes.
- 5. Present with Assurance: Deliver professional valuation insights to bolster your decision-making process.
Why Choose This Calculator for Seres Therapeutics, Inc. (MCRB)?
- Accuracy: Utilizes real Seres Therapeutics financial data for precise calculations.
- Flexibility: Allows users to easily test and adjust inputs to fit their needs.
- Time-Saving: Eliminate the complexities of creating a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected by top financial professionals.
- User-Friendly: Intuitive design makes it accessible for users with varying levels of financial modeling knowledge.
Who Should Use This Product?
- Individual Investors: Gain insights for making informed decisions about investing in Seres Therapeutics, Inc. (MCRB).
- Financial Analysts: Enhance valuation methodologies with comprehensive financial models tailored for Seres Therapeutics, Inc. (MCRB).
- Consultants: Provide clients with expert valuation analysis related to Seres Therapeutics, Inc. (MCRB) efficiently and effectively.
- Business Owners: Learn from the valuation strategies of biotech companies like Seres Therapeutics, Inc. (MCRB) to inform your own business approaches.
- Finance Students: Explore real-world valuation techniques through case studies involving Seres Therapeutics, Inc. (MCRB).
What the Template Contains
- Preloaded MCRB Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.